Sonnet to Present at the MedInvest Biotech & Pharma Conference
Sonnet BioTherapeutics (NASDAQ:SONN), a clinical-stage company focused on developing immunotherapeutic drugs for the tumor microenvironment (TME), has announced its participation in the upcoming MedInvest Biotech & Pharma Conference in Palo Alto, California.
Interim CEO Raghu Rao will deliver a presentation on Thursday, September 25, 2025, at 9:40 AM PT. The management team will also be available for one-on-one meetings with qualified investors attending the conference. A live webcast of the presentation will be accessible through the Events page in the Investors section of Sonnet's website.
Sonnet BioTherapeutics (NASDAQ: SONN), azienda clinica in fase di sviluppo di farmaci immunoterapici per il tumore microambiente (TME), ha annunciato la sua partecipazione alla prossima MedInvest Biotech & Pharma Conference a Palo Alto, in California. L'amministratore delegato ad interim Raghu Rao terrà una presentazione giovedì 25 settembre 2025 alle ore 9:40 (PT). Il team di gestione sarà disponibile anche per incontri individuali con investitori qualificati presenti alla conferenza. Una trasmissione in diretta della presentazione sarà accessibile tramite la pagina Eventi nella sezione Investitori del sito di Sonnet.
Sonnet BioTherapeutics (NASDAQ: SONN), empresa en fase clínica centrada en desarrollar fármacos inmunoterapéuticos para el microambiente tumoral (TME), ha anunciado su participación en la próxima conferencia MedInvest Biotech & Pharma Conference en Palo Alto, California. El director general interino Raghu Rao presentará el jueves 25 de septiembre de 2025 a las 9:40 a.m. hora del Pacífico. El equipo de dirección también estará disponible para reuniones individuales con inversores cualificados asistentes a la conferencia. Una transmisión en vivo de la presentación estará disponible a través de la página de Eventos en la sección de Inversores del sitio web de Sonnet.
Sonnet BioTherapeutics(NASDAQ: SONN)는 종양 미세환경(TME)을 겨냥한 면역치료제 개발에 집중하는 임상 1상 기업으로, 다가오는 MedInvest Biotech & Pharma Conference에 Palo Alto, California에서 참가한다고 발표했습니다. 임시 CEO Raghu Rao가 2025년 9월 25일 목요일 오전 9:40 PDT에 발표를 진행합니다. 컨퍼런스에 참석하는 자격 있는 투자자들과의 1:1 면담도 경영진이 가능하며, 발표의 실시간 방송은 Sonnet 웹사이트의 투자자 섹션 내 Events 페이지에서 확인할 수 있습니다.
Sonnet BioTherapeutics (NASDAQ: SONN), société en phase clinique spécialisée dans le développement de médicaments immunothérapeutiques pour le microenvironnement tumoral (TME), a annoncé sa participation à la prochaine MedInvest Biotech & Pharma Conference à Palo Alto, en Californie. Le PDG par intérim Raghu Rao présentera le jeudi 25 septembre 2025 à 9h40 (PT). L’équipe de direction sera également disponible pour des entretiens individuels avec les investisseurs qualifiés présents à la conférence. Une retransmission en direct de la présentation sera accessible via la page Événements de la section Investisseurs du site de Sonnet.
Sonnet BioTherapeutics (NASDAQ: SONN), ein klinisch in der Entwicklung befindliches Unternehmen, das Immuntherapien für das Tumormikroumfeld (TME) entwickelt, hat seine Teilnahme an der kommenden MedInvest Biotech & Pharma Conference in Palo Alto, Kalifornien, angekündigt. Interims-CEO Raghu Rao wird am Donnerstag den 25. September 2025 um 9:40 Uhr Pazifische Zeit eine Präsentation halten. Das Management-Team steht auch für Einzelgespräche mit qualifizierten Investoren zur Verfügung, die an der Konferenz teilnehmen. Eine Live-Übertragung der Präsentation ist über die Events-Seite im Investorenbereich der Sonnet-Website verfügbar.
Sonnet BioTherapeutics (NASDAQ: SONN)، شركة في المرحلة السريرية تركز على تطوير أدوية مناعية لعلاج بيئة الورم الدقيقة (TME)، أعلنت عن مشاركتها في مؤتمر MedInvest Biotech & Pharma Conference القادم في بالو ألتو، كاليفورنيا. سيقدم المدير التنفيذي المؤقت راجو راو عرضاً يوم الخميس 25 سبتمبر 2025 الساعة 9:40 صباحاً بتوقيت المحيط الهادئ. كما سيكون فريق الإدارة متاحاً للاجتماعات الفردية مع المستثمرين المؤهلين القادمين إلى المؤتمر. يمكن الوصول إلى البث المباشر للعرض من خلال صفحة الأحداث في قسم المستثمرين على موقع Sonnet.
Sonnet BioTherapeutics (NASDAQ: SONN)，一家处于临床阶段、专注于为肿瘤微环境（TME）开发免疫治疗药物的公司，宣布将参加在加利福尼亚州帕洛阿尔托举行的 MedInvest Biotech & Pharma Conference。临时首席执行官 Raghu Rao 将于 2025 年 9 月 25 日（周四）太平洋时间上午 9:40 进行演讲。管理团队也将为参加会议的合格投资者提供一对一会谈的机会。演讲的现场网络广播可以通过 Sonnet 官网投资者板块的 Events 页面观看。
- None.
- None.
Live webcast presentation on Thursday, September 25th at 9:40 AM PT
PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that Raghu Rao, Interim Chief Executive Officer of Sonnet, will present on Thursday, September 25, 2025 at 9:40 AM PT at the MedInvest Biotech & Pharma Conference being held in Palo Alto, California.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (sonnetbio.com)
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin-Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.
Sonnet’s lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors, certain types of sarcoma, and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study through a Master Clinical Trial and Supply Agreement, along with ancillary Quality and Safety Agreements, with Roche in combination with atezolizumab (Tecentriq®) for the treatment of platinum-resistant ovarian cancer (PROC) (NCT05756907). The Company is also evaluating its second program using this platform, SON-1210, an IL12-FHAB-IL15 for solid tumors, in collaboration with the Sarcoma Oncology Center to commence an investigator-initiated and funded Phase 1/2a study for the treatment of pancreatic cancer.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908-824-0775
SONN@jtcir.com
FAQ
When is Sonnet BioTherapeutics (SONN) presenting at the MedInvest Conference?
Who will be presenting for Sonnet BioTherapeutics at the MedInvest Conference?
How can investors access Sonnet BioTherapeutics' MedInvest Conference presentation?
What type of company is Sonnet BioTherapeutics (SONN)?
